Vivex Biologics has raised $30.4M across 3 funding rounds, plus 1 undated round.
3 funding rounds, the latest highlighted.
Vivex Biologics was founded in 2012, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $7.2M raised.
A primary round — the company sells new shares to investors it selects. $6.6M raised.
No filing has been made.
3 dated rounds, newest first.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Vivex Biologics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
